


CLAIMS

1. A quinuclidine derivative represented by Formula II




5

wherein

----- represents an optional double bond;

10 n is 1, 2 or 3;

X represents a linker selected from -O-, -O-CH₂-, -O-CH₂-CH₂-, -S-, -SO-,
 -SO₂-, -CH₂-, -S-CH₂-CH₂-, -CH₂-, -C(=CH₂)-, -NH-, -N(alkyl)-, -C(=O)-, -C(=S)-,



15

Y represents O, S, SO₂, or NR', wherein R' represents hydrogen or alkyl.20 2. The quinuclidine derivative of claim 1, wherein ----- represents a single (covalent) bond.

25 3. The quinuclidine derivative of either one of claims 1-2, wherein n is 1, 2 or 3.

4. The quinuclidine derivative of any one of claims 1-3, wherein X
 25 represents a linker selected from -O-, -O-CH₂-, -O-CH₂-CH₂-, -S-, and -CH₂-.30 5. The quinuclidine derivative of any one of claims 1-4, wherein Y represents O, S, SO₂, or NR', wherein R' represents hydrogen or alkyl.6. The quinuclidine derivative of claim 5, which is
 (±)-3-(Dibenzofuran-2-yloxy)-1-azabicyclo[2.2.2]octane;

or an enantiomer thereof, or a pharmaceutically-acceptable addition salt thereof, or an onium salt thereof.

7. A pharmaceutical composition comprising a therapeutically effective amount of a quinuclidine derivative of any one of claims 1-6, or a pharmaceutically-acceptable addition salt thereof.

8. Use of a quinuclidine derivative of any one of claims 1-6, or a pharmaceutically-acceptable addition salt thereof, for the manufacture of a pharmaceutical composition/medicament for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of cholinergic receptors and/or monoamine receptors.

15 9. The use according to claim 8, wherein the disease, disorder or condition relates to the central nervous system.

10. The use according to claim 9, wherein the disease, disorder or condition is anxiety, cognitive disorders, learning deficit, memory deficits and dysfunction, 20 Alzheimer's disease, attention deficit, attention deficit hyperactivity disorder (ADHD), Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Gilles de la Tourette's syndrome, psychosis, depression, mania, manic depression, schizophrenia, obsessive compulsive disorders (OCD), panic disorders, eating disorders such as anorexia nervosa, bulimia and obesity, narcolepsy, nociception, AIDS-dementia, senile 25 dementia, peripheric neuropathy, autism, dyslexia, tardive dyskinesia, hyperkinesia, epilepsy, bulimia, post-traumatic syndrome, social phobia, sleeping disorders, pseudodementia, Ganser's syndrome, pre-menstrual syndrome, late luteal phase syndrome, chronic fatigue syndrome, mutism, trichotillomania, and jet-lag.

30 11. The use according to claim 8, wherein the disease, disorder or condition are associated with smooth muscle contractions, including convulsive disorders, angina pectoris, premature labour, convulsions, diarrhoea, asthma, epilepsy, tardive dyskinesia, hyperkinesia, premature ejaculation, and erectile difficulty.

35 12. The use according to claim 8, wherein the disease, disorder or condition is related to the endocrine system, such as thyrotoxicosis, pheochromocytoma, hypertension and arrhythmias.

13. The use according to claim 8, wherein the disease, disorder or condition is a neurodegenerative disorders, including transient anoxia and induced neurodegeneration.

5 14. The use according to claim 8, wherein the disease, disorder or condition is an inflammatory disorder, including inflammatory skin disorders such as acne and rosacea, Chron's disease, inflammatory bowel disease, ulcerative colitis, and diarrhoea.

10 15. The use according to claim 8, wherein the disease, disorder or condition is mild, moderate or even severe pain of acute, chronic or recurrent character, pain caused by migraine, postoperative pain, phantom limb pain, neuropathic pain, chronic headache, central pain, pain related to diabetic neuropathy, to post therapeutic neuralgia, or to peripheral nerve injury.

15

16. The use according to claim 8, wherein the disease, disorder or condition is associated with withdrawal symptoms caused by termination of use of addictive substances, including nicotine containing products such as tobacco, opioids such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine-like drugs, and 20 alcohol.

17. A method of treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to modulation of cholinergic receptors and/or 25 monoamine receptors, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a quinuclidine derivative of any one of claims 1-6.